To The Editor: In the MENDS trial, Dr Pandharipande and colleagues1 concluded that dexmedetomidine infusion resulted in more days alive without delirium or coma and more time at the targeted level of sedation than with a lorazepam infusion. It remains unclear whether the study findings are due to the benefits of dexmedetomidine or are a result of the study design itself.
Wunsch H, Meltzer JS. Sedation With Dexmedetomidine vs Lorazepam in Mechanically Ventilated Patients. JAMA. 2008;299(13):1540-1542. doi:10.1001/jama.299.13.1540-b